Clinical Trials
135 trialsCaDAnCe-101
BeOne Medicines
MAHOGANY
BeOne Medicines
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
BAF_FRontier-1
Eli Lilly and Company
OLYMPIA-5
Regeneron Pharmaceuticals
EPCORE™ NHL-1
Genmab
EPCORE™ NHL-3
Genmab
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
LYMFOR
Pentixapharm AG
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Adicet Therapeutics
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
CLOVER-WaM
Cellectar Biosciences, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Atalanta-1
Lakefront Biotherapeutics NV
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
SIDNEY
Enterome
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
RUBIN
iOMEDICO AG
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie
ZUMA-5
Gilead Sciences
InMIND
Incyte Corporation
ELiPSE-1
Century Therapeutics, Inc.
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc.
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
TRANSCEND FL
Celgene
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Acerta Pharma BV
ELM-2
Regeneron Pharmaceuticals
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
ARIADNE
iOMEDICO AG
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd